UPClytics
EnglishDeutsch
Sign inSign up
View all cases

UPC CFI 503/2024

Sep 2, 2024·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Parent infringement case:UPC CFI 148/2024

Case details
Status
Case Closed
Action
Counterclaim for revocation
Category
Counter Claim for Revocation
Parties
Respondents
Reps: Agathe Michel-De Cazotte; Frédéric Chevallier
Division
Munich LD
Judges
Technology
Pharmaceuticals · Small Molecule · Pharmaceutical & Medical
Language
English
First decided
Dec 12, 2025
Documents
Document titleDatePublic
Note2026-03-11Not public
Note2026-02-06Not public
Receipt2026-02-04Not public
Cover sheet2026-02-04Not public
Application document Claimant2026-02-04Not public
Receipt2026-01-12Not public
Cover sheet2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Application document Applicant2026-01-12Not public
action.phaseChange.caseClose2025-12-16Not public
Decision2025-12-16Public
action.issueDecision.decision2025-12-12Not public
Decision2025-12-12Not public
Other Documents2025-11-25Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
oral hearing reference - IC2025-09-15Not public
oral hearing reference - IC2025-09-15Not public
Fix-Interim-Conference-Date2025-09-10Not public
Interim-Conference-Decision2025-09-10Not public
Written-Procedure-Closure2025-09-10Not public
Acknowledgement-of-lodging2025-08-08Not public
Exhibit No. B.362025-08-08Not public
Exhibit No. B.352025-08-08Not public
Exhibit No. B.322025-08-08Not public
Exhibit No. B.402025-08-08Not public
Exhibit No. B.2.2.22025-08-08Not public
Exhibit No. B.392025-08-08Not public
Exhibit No. 0.52025-08-08Not public
Exhibit No. B.412025-08-08Not public
Rejoinder2025-08-08Not public
Exhibit No. B.422025-08-08Not public
Exhibit No. B.372025-08-08Not public
Exhibit No. B.382025-08-08Not public
Exhibit No. B.432025-08-08Not public
Exhibit No. B.312025-08-08Not public
Exhibit No. B.302025-08-08Not public
Exhibit No. B.2.2.12025-08-08Not public
Exhibit No. B.332025-08-08Not public
Exhibit No. B.342025-08-08Not public
Exhibit No. B.22.1bis2025-08-08Not public
Acknowledgement-of-change-of-a-representative2025-07-10Not public
Acknowledgement-of-lodging2025-07-08Not public
Exhibit_TW_D_14_signed2025-07-08Not public
Exhibit_DFMP_D115_signed2025-07-08Not public
Exhibit_TW_D_16_signed2025-07-08Not public
Exhibit_TW_D_15_signed2025-07-08Not public
Exhibit_DFMP_D114_signed2025-07-08Not public
Exhibit_TW_D_17_signed2025-07-08Not public
2025 07 08 Sanovi vs. Zentiva_ZENTIVA_Rejoinder Infringement_Reply Counterclaim_signed2025-07-08Not public
Application-RoP293-Receipt2025-07-08Not public
Formal-checks_Notification-of-positive-outcome2025-07-08Not public
Application-RoP2932025-06-27Not public
Application2025-06-27Not public
Outcome of the Order2025-05-08Not public
final order2025-05-08Public
final order2025-05-08Not public
Receipt2025-04-11Not public
Exhibit TW D 11_signed2025-04-09Not public
Exhibit TW D 10_signed2025-04-09Not public
Exhibit TW D 12B_373-740_signed2025-04-09Not public
2025 04 09 Sanofi_v_Zentiva_ZENTIVA_Reply to Sanofi Comments No 2 R. 105_signed2025-04-09Not public
Exhibit TW D 12A_1-372_signed2025-04-09Not public
Exhibit TW D 9_signed2025-04-09Not public
Headnote-and-Keywords2025-01-24Not public
Hearing-Dates2025-01-24Not public
scheduling IC and OH for CC2025-01-24Public
Hearing-Dates2025-01-24Not public
Outcome of the Order2025-01-17Not public
R 305 second - final2025-01-17Public
Hearing Reference2025-01-16Not public
Hearing Reference2025-01-16Not public
Hearing-Dates2025-01-13Not public
R 305 second- oral comments2025-01-13Not public
Receipt2025-01-09Not public
Application2025-01-09Not public
Exhibit No. A.02.22025-01-09Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Notification Of Service2024-09-30Not public
Zustellnachweis2024-09-30Not public
Acknowledgement of access to case2024-09-25Not public
epoUploadDocumentsWorkflow2024-09-17Not public
Document from EPO2024-09-16Not public
Letter for Service2024-09-04Not public
Panel-Appointment2024-09-04Not public
EPO-Request-for-case-pending2024-09-04Not public
Acknowledgement-of-lodging2024-09-04Not public
Formal-checks_Notification-of-positive-outcome2024-09-04Not public
DFMP P4 - Priority document US 61_3558882024-09-02Not public
DFMP D14 - FDA label for docetaxel (Taxotere) 20072024-09-02Not public
DFMP D29 - Tannock et al.2024-09-02Not public
DFMP P3 - Priority document US 61_3558342024-09-02Not public
DFMP P2 - Priority document US 61_2939032024-09-02Not public
DFMP D112 - Excerpt from the online National Cancer Institute_s Drug Dictionary re. cabazitaxel2024-09-02Not public
TW D 8 - DE Leaflet Cabazitaxel2024-09-02Not public
TW D 5 - FR SMPC Cabazitaxel2024-09-02Not public
DFMP P6 - Priority document US 61_3839332024-09-02Not public
DFMP D111 - INN Publication 20082024-09-02Not public
DFMP D109 - Albarqouni2024-09-02Not public
TW D 7 - DE SMPC Cabazitaxel2024-09-02Not public
TW D 7 - DE SMPC Cabazitaxel2024-09-02Not public
DFMP D90 - Goetz et al.2024-09-02Not public
DFMP D15 - de Bono et al.2024-09-02Not public
DFMP D10 - Sanofi-Aventis Press Release_ 21 December 20092024-09-02Not public
DFMP D9 - Galletti et al.2024-09-02Not public
DFMP D105 - Sava et al.2024-09-02Not public
DFMP D110 - Consolidated List of documents EPO2024-09-02Not public
DFMP D108 - Barraclough and Davis2024-09-02Not public
DFMP P1 - Priority document US 61_2561602024-09-02Not public
TW D 2 - Medicines for Europe2024-09-02Not public
DFMP D26 - Attard et al.2024-09-02Not public
DFMP D11 - Les Echos_ 22 Dec 20092024-09-02Not public
TW D 8 - DE Leaflet Cabazitaxel2024-09-02Not public
DFMP D2 - National Horizon Scanning Centre2024-09-02Not public
DFMP D72 - Scher et al.2024-09-02Not public
DFMP D13 - Pivot et al.2024-09-02Not public
DFMP D35 - Leaflet Aventis Oncology 20032024-09-02Not public
TW D 4 - ANSM Cabazitaxel2024-09-02Not public
TW D 6 - FR Leaflet Cabazitaxel2024-09-02Not public
DFMP D38 - Sanofi Press Release_September 17 20072024-09-02Not public
DFMP P5 - Priority document US 61_3699292024-09-02Not public
TW D 5 - FR SMPC Cabazitaxel2024-09-02Not public
DFMP D18 - EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man 20062024-09-02Not public
DFMP D113 - US Code of Federal Regulations Title 21_Chapter I_Part 3142024-09-02Not public
DFMP D91 - Bissery et al.2024-09-02Not public
DFMP D4 - Mita et al.2024-09-02Not public
DFMP D25 - Correspondence_Lancet_2011_377_121-1222024-09-02Not public
DFMP D7 - Beardsley et al.2024-09-02Not public
DFMP D3a - Blog post by Dr. Barry Mirtsching 12 October 20072024-09-02Not public
DFMP D37 - Winquist et al.2024-09-02Not public
DFMP P7 - Priority document US 61_389,9692024-09-02Not public
2024 09 02 Sanofi vs. Zentiva Statement of Defence and Counterclaim for Revoc2024-09-02Not public
TW D 3 - Report EU Commission2024-09-02Not public
TW D 6 - FR Leaflet Cabazitaxel2024-09-02Not public
DFMP D103 - Fossa. et al.2024-09-02Not public
DFMP D21 - EMA Assessment Report for Jevtana (cabazitaxel) January 20 20112024-09-02Not public
DFMP D3b - Further blog post by Dr. Mirtsching July 6 20072024-09-02Not public
DFMP D104 - Tannock_Clin. Oncol. 19962024-09-02Not public
TW D 4 - ANSM Cabazitaxel2024-09-02Not public
DFMP D102 - Tannock_Clin. Oncol. 19892024-09-02Not public
DFMP D1 - Sanofi-Aventis - XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone2024-09-02Not public
DFMP D11 - Les Echos_ 22 Dec 20092024-09-02Not public